Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Pathogenic variants in the MME gene cause dominant and recessive late-onset axonal hereditary neuropathy, that is, axonal Charcot-Marie-Tooth syndrome (LOCMT2). Here, we report next-generation sequencing (NGS) and Sanger sequencing (SS) results of 28 LOCMT2 patients carrying either the repeatedly reported c.467del p.(Pro156Leufs*14) or the c.440–2A>C variants. We demonstrate that an intronic AT-repeat in close proximity to these two mutations is frequently causing an allele dropout during SS that result in false genotyping in a considerable proportion of patients. This may result in an incorrect diagnosis, which has a considerable clinical impact for genetic counselling and prognosis.
Recent studies have demonstrated that both heterozygous and biallelic variants in MME (encoding the metalloprotease neprilysin) are a frequent cause of LOCMT2 (MIM: 617017).1–3 The heterozygotes variants cause a milder phenotype with reduced penetrance. Besides the large spectrum of rare or even single pathogenic MME variants, the frameshift deletion c.467del p.(Pro156Leufs*14) and the splice site mutation c.440–2A>C have been recurrently reported in patients with autosomal dominant and autosomal recessive LOCMT2.2–4 Although PCR is considered to be a robust technology and a reliable tool to be used for routine diagnosis, allele-specific sequence variations occasionally may provoke amplification failure of one of the two alleles at a given locus.5 Such an allele dropout has also been shown for the c.467del mutation in MME in one consanguineous family.4
In this study, registries at the Medical University of Vienna and Telemark Hospital Trust were searched for LOCMT2 individuals carrying the MME variants NM_007289.3:c.467del p.(Pro156Leufs*14) and NM_007289.3:c.440–2A>C. We ascertained 28 individuals from 16 families (MH1-MH16) afflicted with LOCMT2. For segregation analysis three healthy family members were also included. The families originated from Austria, Germany, Norway and Sweden.
Whole exome sequencing, NGS-based multigene panel sequencing or SS of the MME gene was performed and analysed as reported previously.3 SS was used to confirm MME variants detected by NGS and for segregation analysis in families. Due to conflicting results between NGS and SS at both laboratories, sequencing was repeatedly carried out using primers either including or excluding the adjacent AT-repeat of variable size, c.439+33_439+48AT[8-15], located 57 bp 5’ of exon 6 (online supplemental material 1). Subsequently, six additional enzymes and two additional conditions for the original AccuPrime Taq DNA Polymerase System were tested to unravel the PCR enzymes’ ability to amplify both the short and the long AT-repeat. A full list of the primers, enzymes and conditions used is described in the online supplemental material 1.
Moreover, the length of the intronic AT-repeats was assessed on 179 selected DNA samples by using NGS data, fragment length analysis (FLA) and/or multiplex ligation-dependent probe amplification (MLPA). FLA details are described in the online supplemental material 1, MLPA and NGS followed procedures as described.2 3
Tracking of the c.467del p.(Pro156Leufs*14) and the c.440–2A>C MME mutations previously detected by NGS or SS revealed conflicting results in 7/28 (25%) of the patients when using the original SS primers including the AT-repeat (table 1). In three families, MH-1, MH-2 and MH-6, the c.467del variant was first detected as heterozygous by NGS, but turned out to be homozygous by SS in several family members. On the other hand, in family MH-14, the index patient was tested heterozygous for the c.440–2A>C variant by NGS, whereas the same mutation was absent by SS. To unravel these discrepancies, an alternative primer-set excluding the intronic AT-repeat was used for SS. This enabled a correct determination of the MME mutation status. The pedigrees and sequence traces are depicted in figure 1A,B. Additional sequences traces are provided in the online supplemental material 1. Furthermore, the length of the AT-repeat was tested by NGS and/or FLA and MLPA. Thereby, it turned out, that all seven patients with contradicting results were compound heterozygous for a short (8–9) and an expanded (13–15) AT-repeat, suggesting allele dropout of the expanded AT-allele. The incorrect determination of the mutation status did not occur in 17 patients who were homozygous for a short or a long AT-repeat on NGS/FLA (table 1).
To determine the frequency of long and short AT-repeats, results of 179 additional individuals were evaluated. Thereby, 34% carried a homozygously short (up to 9 AT-repeats), 22% a homozygously long AT-repeat (12–16 AT-repeats) and 44% where compound heterozygous, giving an allele frequency of 56% for a short and 44% for a long AT-repeat. Data from the gnomAD database (broadinstitute.org) show a similar distribution. In the non-Finish European population, the allele frequency is 62.4% for a short and 37.6% for a long AT-repeat. The high frequency of a compound heterozygous AT-repeat bears a high risk to achieve incorrect results.
Finally, we investigated whether the use of different PCR enzymes circumvents allelic dropouts. These experiments showed that only three out of eight enzymes tested and none of the two specific conditions tested were able to amplify the expanded AT-allele in the presence of a short AT-allele (online supplemental material 1).
FLA indicated that the allele dropout likely occurs during PCR. Comparison of signal intensities for the AccuPrime enzyme and the Type-it Microsatellite PCR kit, of which the first caused allele dropout in SS whereas the latter not, showed that the signal intensity from the expanded AT-allele was substantially lower with the AccuPrime enzyme (figure 1C).
In summary, we identified that a short increase in an AT-repeat close to two MME hotspot mutations leads to allele dropout during SS and subsequent false interpretation of the results in several patients. A false positive prediction of a homozygous MME mutation would imply earlier onset, a more severe disease course and a high recurrence risk to offspring, whereas a false negative diagnosis could influence further diagnostic and therapeutic procedures and has an impact for genetic counselling. Although to date, NGS is frequently applied for routine diagnostics, SS is still used for verification of a particular variant and segregation analysis in a family. The fact that a small increase in a repetitive sequence may lead to amplification failure is important to bear in mind when designing primers for SS as it may be relevant for other genes as well.
Data availability statement
Data supporting the findings of this study are available from the corresponding author on reasonable request.
Patient consent for publication
The study was approved by the ethics committee of the Medical University of Vienna, ID EVS 1738/2012. All participants recruited by the Medical University of Vienna gave written informed consent for involvement in the study. Data from the Norwegian families were provided in de-identified form after approval by the Norwegian Centre for Research Data and the data protection officer at Telemark Hospital Trust.
We thank the participating patients and their families for their cooperation. We would like to thank Ewelina Rojek-Jenssen for contributing with SS at Telemark Hospital Trust.
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Contributors HH, HTH, MA-G: conception and design of the study. HH, HTH, RS-P, GJB, PMA, CB, SH, ØLH, IK, WL, SBCFR, SR-S, LS, RW, MW-B, JS, MA-G: acquisition and/or analysis of data. HH, RS-P, MA-G: drafting the text. All authors read and approved the final manuscript.
Funding This project was supported by the Austrian Science Fund (FWF) (MA-G) and the Deutsche Forschungsgemeinschaft (DFG) (IK, JS), under the frame of EJP RD, the European Joint Programme on Rare Diseases. In addition, this project has received funding from the European Union’s Horizon 2020 research and innovation programme under the EJP RD COFUND-EJP N° 825 575. JS is supported by the Fritz-Thyssen-Stiftung (Az.10.15.1.021MN) and the BMBF (01GM1511B). HH received funds from the South Eastern Norway Regional Health Authority (HSØ): research grant #2016133 and #2021097.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.